Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

NCT05526313 | Completed Phase 1

• 1 other identifier: GZ2018-001-1.0
• Study Type: interventional
• Target: 29
• Locations: 1 country
• Sites: 1

Brief Summary

Purinostat mesylate for injection (PM) was the novel and highly potent Class I a and IIb HDAC-selective inhibitors. The results of regular blood sampling analysis of the mouse B-cell lymphoma model induced by ighmyc transgenic mice showed that the treatment of PM in each group reduced the proportion of peripheral blood tumor cells in mice. Therefore, PM has the potential to treat diffuse large B cell lymphoma. The results of in vitro enzymatic activity screening showed that PM has high inhibitory activity on HDAC tumors (including HDAC1, 2, 3, 8 subtypes) and type II HDACs (including HDAC6, 10 isoforms), which are closely related to tumors in the HDAC family. Therefore, the results of in vitro enzyme activity screening showed that the IC50 values of PM for inhibiting HDAC1, HDAC2, HDAC3, HDAC8, HDAC6, and HDAC10 subtypes of HDAC class I and HDAC class IIb were 0.81, 1.4, 1.7, 3.8, 11.5, and 11 nM, respectively. However, the inhibitory activity of HDAC IIa and HDAC IV enzymes was low, and its IC50 values for HDAC4, HDAC5, HDAC7, HDAC9, and HDAC11 subtypes of HDAC IIa and HDAC IV were 1072, 426, 590, 622, and 3349 nM, respectively. These data means PM exist high selectivity for tumor-associated HDAC class I and HDAC IIb. Compared with the blank control group, the body weight of the tumor-bearing animals in each dose of PM group did not decrease seriously during the treatment process, and the animals were in good condition during the whole experiment, indicating that the PM is efficacy and safe. During the course of the experiment, the tumor cell population (GFP+, B220+) in the blood of the animals basically regressed after treatment with Prilistat hydrochloride. Research purposes: Main purpose: Observation of patients with relapsed or refractory hematological tumors (including but not limited to after standard therapy) mainly in patients with relapsed or refractory B cell-related tumors. Tolerability and safety of B-cell lymphoma, multiple myeloma, B-cell acute leukemia, T-cell lymphoma, T-cell acute leukemia) with disease progression or ineligible for standard therapy. To observe the dose-limiting toxicity (DLT) in patients with relapsed or refractory B cell-related tumors and hematological tumors, and determine its maximum tolerated dose (MTD), which is the maximum tolerated dose (MTD). Phase II clinical dosing schedule provides the basis. Secondary Purpose: To evaluate the pharmacokinetic parameters of patients with relapsed or refractory B-cell-related tumors and hematological tumors after single and multiple intravenous infusions of priinostat mesylate for injection. To evaluate the pharmacodynamics of patients with relapsed or refractory B cell-related tumors and hematological tumors after single and multiple intravenous infusions of priinostat mesylate for injection. To preliminarily observe the efficacy of Priinostat mesylate for injection in the treatment of patients with relapsed or refractory hematological tumors, mainly patients with B cell-related tumors.

Conditions

Diffuse Large B Cell Lymphoma，DLBCL

Outcome Measures

Primary Outcomes (10)

• Purinostat Mesylate Pharmacokinetics (PK)：Cmax

  Estimation of maximum observed plasma concentration

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：Tmax

  Estimation of time to reach Cmax

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：AUC0-72h

  Estimation of AUC from time zero to the last measured time point

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：AUC0-∞

  Estimation of AUC from time zero extrapolated to infinity

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：MRT

  Estimation of mean residence time

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：Vd

  Estimation of apparent volume of distribution

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：t1/2

  Estimation of terminal elimination half-life

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：CLz/F

  Estimation of clearance when dosed orally

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：Vz/F

  Estimation of apparent volume of distribution when dosed orally

  72hours

• Purinostat Mesylate Pharmacokinetics (PK)：Ke

  Estimation of the elimination rate constant of a drug in the body

  72hours

Study Arms (7)

1.2mg/m^2

EXPERIMENTAL

Drug: Purinostat Mesylate 1.2mg/m^2

2.4mg/m^2

EXPERIMENTAL

Drug: Purinostat Mesylate 2.4mg/m^2

4.0mg/m^2

EXPERIMENTAL

Drug: Purinostat Mesylate 4.0mg/m^2

6.0mg/m^2

EXPERIMENTAL

Drug: Purinostat Mesylate 6.0mg/m^2

8.4mg/m^2

EXPERIMENTAL

Drug: Purinostat Mesylate 8.4mg/m^2

11.2mg/m^2

EXPERIMENTAL

Drug: Purinostat Mesylate 11.2mg/m^2

15mg/m^2

EXPERIMENTAL

Drug: Purinostat Mesylate 15mg/m^2

Interventions

Purinostat Mesylate 1.2mg/m^2 DRUG

1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.

1.2mg/m^2

Purinostat Mesylate 2.4mg/m^2 DRUG

Take the medicine once on D1, D8, D11, D15.

2.4mg/m^2

Purinostat Mesylate 4.0mg/m^2 DRUG

Take the medicine once on D1, D8, D11, D15.

4.0mg/m^2

Purinostat Mesylate 6.0mg/m^2 DRUG

Take the medicine once on D1, D8, D11, D15.

6.0mg/m^2

Purinostat Mesylate 8.4mg/m^2 DRUG

Take the medicine once on D1, D8, D11, D15.

8.4mg/m^2

Purinostat Mesylate 11.2mg/m^2 DRUG

Take the medicine once on D1, D8, D11, D15.

11.2mg/m^2

Purinostat Mesylate 15mg/m^2 DRUG

Take the medicine once on D1, D8, D11, D15.

15mg/m^2

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Age 18 to 70 years old, gender is not limited;
• \. Hematological tumors, including but not limited to B-cell lymphoma, multiple myeloma, B Cell acute leukemia, T-cell lymphoma, T-cell acute leukemia, and patients with disease progression, relapse, or ineligibility for standard regimen therapy after standard regimen therapy ;
• \. Patients without serious organic lesions in the heart, lung, liver and kidney (LVEF (left ventricular ejection fraction \>=50%; total bilirubin \<=1.5×ULN; alanine aminotransferase (ALT) \<=1.5×ULN; aspartate aminotransferase); (AST) \<=1.5×ULN (; serum creatinine\<=1.5×ULN or CCr\>40mL/min);
• \. Those without severe coagulation dysfunction (PT\<=1.5×ULN, APTT\<=1.5×ULN, TT\<=1.5×ULN and FIB\>=1.0 g/L);
• \. Patients without severe hematopoietic dysfunction (absolute neutrophil value\>=1.5×109/L, platelets \>=75×109/L, hemoglobin\>=80g/L), and no platelet, red blood cell, hemoglobin;
• \. Patients received at least 4 weeks or more than 5 half-lives after the last antitumor treatment (chemotherapy, radiotherapy, biological therapy or immunotherapy) before enrollment;
• \. Expected survival time\>= 12 weeks;
• \. ECOG score \<=2 points;
• \. Those who agree to participate in this study and sign the informed consent form.

You may not qualify if:

• \. The toxicity of previous anticancer therapy has not recovered to grade I or below, or has not fully recovered from previous surgery;
• \. Those with severe heart, lung, liver, kidney, digestive system diseases and chronic diseases of vital organs
• \. Pregnant or breastfeeding female patients, fertile female/male patients who refuse to use contraceptive measures during the trial;
• \. A history of acute myocardial infarction, congestive heart failure, unstable angina pectoris, or stroke within 6 months before enrollment;
• \. Patients with impaired cardiac function (ejection fraction \<45% detected by echocardiography or complete left bundle branch block with ECG ST segment downshift \>1 mm or T wave inversion in two or more channels; congenital ventricular or Atrial arrhythmia, clinically significant tachycardia (\>100 beats/min), bradycardia (\<50 beats/min), ECG QTc \>450 ms (men), QTc \>480 ms (women), or clinically significant cardiac Diseases (such as unstable angina, congestive heart failure, myocardial infarction within 6 months), etc.;
• \. Those with central nervous system lymphoma/leukemia or mental disorders;
• \. Have a history of organ transplantation;
• \. Those with severe active infection;
• \. Known severe hypersensitivity to the test drug and its excipients or HDAC inhibitors;
• \. HCV antigen or antibody positive, HIV antigen or antibody positive, HBsAg positive, HBcAb positive and peripheral blood HBV DNA titer detection \>=1×103 IU/mL;
• \. Alcohol dependence or drug abusers;
• \. Those who have participated in clinical trials of other drugs within the past 1 month;
• \. The researchers conclud that there are other factors that are not suitable for participating in the trial.

Sponsors & Collaborators

• Chengdu Zenitar Biomedical Technology Co., Ltd: lead

Study Sites (1)

West China Hospital Sichuan University

Chengdu, Sichuan, 610000, China

Location

MeSH Terms

Conditions

Dendritic Cell Sarcoma, Interdigitating

Condition Hierarchy (Ancestors)

Histiocytic Disorders, Malignant; Neoplasms by Histologic Type; Neoplasms; Histiocytosis; Lymphatic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Ting Niu, Doctor

  West China Hospital

  PRINCIPAL INVESTIGATOR

• Yongsheng Wang, Doctor

  West China Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 31, 2022
• First Posted: September 2, 2022
• Study Start: August 10, 2020
• Primary Completion: September 7, 2022
• Study Completion: March 29, 2024
• Last Updated: October 1, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)